Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT06817720 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: olverembatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]